Novo Holdings invests €86m in 21st.BIO
Novo Holdings is set to invest €86m in 21st.BIO A/S – a new Danish bioindustrial scale-up company – to boost the production of proteins.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
Novartis AG snags Gyroscope for US$1.5bn
Ocular gene therapy specialist Gyroscope Therapeutics Holdings plc is to be acquired by Novartis AG for up to $1.5bn.
NorthSea Therapeutics completes US$80m Series C financing
Dutch metabolic disease specialist NorthSea Therapeutics NV has baged US$80m in a Series C fundraising co-led by Ysios Capital and Forbion Growth.
TheraVision – an oncolytic virus platform technology
Since virus immunotherapies have the potential to improve therapy responses, we established a platform technology based on Herpes Simplex Virus Type 1 (HSV1). TheraVision constitutes a complete development pipeline including a proprietary HSV1 engineering vector for the modular integration of transgenes, a GMP-compliant production process, and complex preclinical test systems including human tumour and immune cells to demonstrate sensitivity and safety.
Depixus raises €30.6m in Series A financing
French-British magnetic trap specialist Depixus has raised €30,6m to develop a commercial instrument based on the company’s MAGNA technology.
Ichnos Sciences in licence deal with Almirall
Ichnos Sciences Inc. has licenced the gobal rights on its IL-1RAP antagonistic antibody ISB 880 to Almirall SA for the treatment of autoimmune disorders.
Vifor Pharma Ltd to be acquired for CHF10.9bn
Biologicals and vaccine specialist CSL Ltd is set to acquire Swiss Vifor Pharma Ltd for CHF10.9bn.
Fapon Biotech Races to Introduce Omicron Neutralizing Antibodies Titer Testing Solution
Given Omicron Varinat’s potential higher rate of transmissibility, Fapon Biotech has successfully introduced SARS-CoV-2 Omicron Variant Neutralizing Antibody Titer Testing Solution (ELISA) to effectively evaluate the immune evasiveness and vaccine effectiveness on Omicron varian.
Apogenix gets €25.8m cash injection for asunercept
German Apogenix AG has received a €26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients.
British Adendra Therapeutics closes $53m financing
The 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners).